2. Introduction
History
CDC classification
Potential agents of bioterrorism
Role of Public Health system in bioterrorism attack
3. Introduction
Bioterrorism involves the deliberate release of viruses, bacteria, or their by-
products (e.g., toxin) to cause morbidity and mortality in humans, animals, or
plants.
All bioterrorism agents are naturally occurring organisms or toxins that can cause
sporadic disease under natural circumstances, but on occasion, medical
manipulation has been attempted to increase resistance to antibiotics or increase
organism virulence.
Bioterrorism is an attractive weapon because biological agents are relatively easy
and inexpensive to obtain, can be easily disseminated, and can cause widespread
fear and panic beyond the actual physical damage.
4. Key Features of Biologic Agents Used as
Bioweapons
High morbidity and mortality
Potential for person-to-person spread
Low infective dose and highly infectious by aerosol
Lack of rapid diagnostic capability
Lack of universally available effective vaccine
Potential to cause anxiety
Availability of pathogen and feasibility of production
Environmental stability
Database of prior research and development
Potential to be “weaponized”
9. Classification
Centers for Disease Control and Prevention (CDC) classifies potential
biologic threats into three categories: A, B, and C
Category A agents are the highest-priority pathogens:
can be easily disseminated or transmitted from person to person
result in high mortality rates
have the potential for major public health impact
might cause public panic and social disruption
require special action for public health preparedness
11. Category B agents include those that are moderately easy to disseminate, result in
moderate morbidity rates and low mortality rates, and require specifically
enhanced diagnostic capacity
13. Category C Agents
These agents have the future potential for engineering for easy dissemination or
high mortality.
Influenza (novel strain)
Nipah virus
Typhus disease (Rickettsia prowazekii)
Viral encephalitis (alphaviruses [e.g., Venezuelan equine
encephalitis, eastern equine encephalitis, western equine
encephalitis])
Water safety threats (e.g., Vibrio cholerae, Cryptosporidium
parvum)
14. Anthrax
Anthrax is caused by a sporulating gram-positive rod, Bacillus anthracis
Human disease largely occurs through contact with animal products, such as
animal skins, where the bacillus form converts back to the spore form.
In 2001, however, 22 cases of anthrax occurred in the United States as an act of
bioterrorism through the postal system, placing anthrax on the forefront of
bioterrorism.
15. Disease occurs when the spore form is introduced subcutaneously or via inhalation,
becomes the vegetative (bacillus) form, and starts replication. Endotoxin secretion,
along with a thick capsule that avoids phagocytosis, leads to local spread, edema,
hemorrhage, and tissue necrosis.
The anthrax capsule, edema factor toxin, and lethal factor toxin act in concert to
drive disease.
16.
17. Clinical features
1) Inhalational anthrax :
Incubation period 1-7days
Within 24 hours, disease rapidly progresses with the development of respiratory
failure, hemorrhagic mediastinitis, necrotizing pneumonia, shock, multiorgan failure
and death.
The development of shock and multiorgan failure can occur rapidly, and along
with the hemorrhagic mediastinitis, is the clinical hallmark of anthrax.
18. Cutaneous anthrax has an incubation period of 7 to 14 days after inoculation of
spores into the subcutaneous space.
Initially a small, painless papule develops that can be pruritic.
The papule enlarges and develops a central vesicle, followed by erosion into a
painless black eschar.
Edema of surrounding tissues, and regional lymphadenopathy is seen along with
systemic symptoms of fever and malaise.
The hands, arms, face, and neck are the most common areas affected.
19. Gastrointestinal anthrax occurs after consumption of undercooked meats of
infected animals.
Bowel edema occurs, followed by mesenteric lymphadenitis and necrosis, with
rapid progression to shock and death.
20.
21. Management
Diagnosis is made by culture of the blood, sputum, pleural fluid, cerebrospinal
fluid, or skin.
Treatment :
Ciprofloxacin
Doxycyclin
22. Small pox
Variola virus is the causative agent of smallpox and is a member of the Poxviridae
family.
Smallpox was eradicated worldwide in 1977 but now has regained interest as a
potential bioterrorism agent.
Due to an increasing unvaccinated population along with its contagiousness and
ability to be transmitted by aerosol, smallpox is a CDC category A bioterrorism
agent.
Only two stockpiles of the virus remain (at the CDC and the Russian State Research
Center) for continued research.
23. Five main clinical categories:
ordinary, - macule , papule, vesicle, pustule
modified, more rapid but less severe
flat,
hemorrhagic,more common in pregnant female
Variola sine eruptione
25. Variola: 4th day of rash
•For the first time-on
the fourth day of the
rash and the fifth day
of infectiousness, a
typical vesicular
appearance is seen
26. Variola major: drying rash (7-9 days)
•The rash is
becoming less
infectious
•Conjunctival
lesions are usually
benign and heal
completely
29. Diagnosis is primarily clinical.
RT PCR is awailable only at Centre for disease control.
Treatment is supportive, with some evidence that cidofivir has activity in animal
model.
30. Plague
Yersinia pestis is the etiologic agent of plague and has caused a number of
pandemics throughout human history.
Transmission to humans occurs by rodent-infected flea bites, infected animal
scratches or bites, exposure to infected humans, and bioterrorism.
31.
32. Clinical features
In bubonic plague, a sudden onset of fevers, chills, and headache is followed by
pain and swelling in the regional lymph nodes proximal to the site of the bite or
scratch.
This lymph node (bubo) is characterized by intense tenderness with erythema and
edema. Fluctuation test is negative.
Septicemic plague occurs with acute fever followed by sepsis without the presence
of a bubo.
Pneumonic plague , has short incubation period and rapidly develops ARDS
33.
34. Management
Diagnosis : clinical diagnosis is difficult
Laboratory diagnosis is primarily by culture of the sputum or blood as Y. pestis
grows well on most laboratory media.
Serology and rapid diagnostic testing by ELISA or PCR is also available but is used
primarily in field testing.
Treatment :
Streptomycin is drug of choice
Gentamycin or doxycycline can also be used.
35. Tularemia
Tularemia is caused by the gram-negative bacterium Francisella tularensis and is a
zoonotic disease, with humans as accidental hosts.
Human infections occur by contact with ticks and flies, handling infected animals,
improperly prepared animal meat, animal scratches and bites, drinking
contaminated water, or aerosolization of the organism from the environment or in
bioterrorism.
Human-to-human transmission does not occur.
36.
37. Clinical features
Six patterns of disease
Ulceroglandular,
Glandular,
Pneumonic,
Oropharyneal,
Oculoglandular
38.
39. Management
Diagnosis : Bacteria is very difficult to grow on culture media.
Diagnosis is made by ELISA or histologic examination showing gram-negative
intracellular organisms.
X ray shows patchy opacities bilaterally,and hilar adenopathy.
Pleural effusions and a miliary pattern can alsooccur, although this is less common.
Mediastinal adenopathy is seen rarely.
Treatment : Genatamycin is drug of choice
Doxycyclin and ciprofloaxacin are 2nd choice
40. Glanders
It is caused by Burkholderia mallei
It is primary a disease of horses. Human is infected due to contact or droplet
infection.
Clinical features : usually acute or chronic skin infection
Droplet infection can cause pneumonia and sepsis rapidly
Usually misclassified on culture as it is a rare disease.
Treatment : Imipenem is the drug of choice
3rd generation cephalosporin, ciorofloxacin are alternative
41. Melioidosis
Caused by Burkholderia pseudomallei.
Soil and water are natural reservoir
Spread to human by direct contact or inhalation
In bioterrorism aerosolisation will lead to pneumonia.
Most patients develop sepsis and MODS rapidly.
Diagnosis is by culture
Treatment : imipenem or 3rd gen cephalsoprin in acute condition followed by
20day treatment with doxycycline or cotrimoxazole.
42. Psittacosis
Psittacosis is caused by Chlamydophila psittaci, an intracellular bacterium routinely
associated with birds such as parrots, cockatiels, and canaries.
Intentional aerosolization would lead to multiple cases of nonspecific “atypical
pneumonia” with cough, fever, and headache.
Diagnosis is by ELISA , difficult to grow on cultures
Treatment is macrolide or doxycycline or ciprofloxacin
43. Q Fever
Q fever is a zoonotic disease caused by Coxiella burnetii.
Cattle, sheep, and goats are the primary reservoirs
It does not cause clinical disease in animals, bacteria is found in milk, urine, feces,
amniotic fluids, and placenta.
Infection by droplet spread.
Clinical features : high fevers (> 104° F), severe headache, myalgia, sore throat,
nonproductive cough, nausea, vomiting, diarrhea, abdominal pain, and chest pain.
Fever usually lasts for 1 to 2 weeks.
Thirty percent to 50% of patients with symptomatic infection will develop
pneumonia
44. Endocarditis, chronic Q fever(>6 months) are rare complications.
Diagnosis is made by indirect immunoflouroscence assay.
Doxycycline 100 mg twice daily for 15 to 21 days is the treatment of choice for Q
fever.
45. Role of physician
The recognition of a bioterrorism event versus a naturally occurring infection relies
on a high suspicion on behalf of the clinician.
However it is difficult in initial stages of disease when symptoms are non specific.
a systematic approach is advocated initially in all febrile respiratory illnesses, with
suspicion and should contact public health when specific clinical findings or
epidemiologic features are detected that lead the clinician to suspect a
bioterrorism or emerging infectious disease event
46.
47. Role Of Public Health System
Being Prepared
Education of medical community
Education of public
Training of special response teams
Participation in exercises for different scenarios
Development of communication systems
Development of interagency protocols
48. Initial Response to BT Induced Disease
Early detection through surveillance/ rapid assessment of reports
Mobilize laboratory
Rapid confirmation of agent, site, initial at-risk population, prophylaxis and/or
treatment
Alert medical community, ERs, labs
Implement disease specific plans (e.g. Smallpox)
Determine resource needs and possible quarantine
Coordinate with partner agencies (local/state/national
49. Continued Response to BT Induced Diseases
Closely monitor communication network for new information
Provide, accurate, timely information to public
Continue epidemiologic investigation to refine at risk population
Assess environmental contamination
Provide or coordinate testing/ prophylaxis/ treatment to at-risk population
Access biological stockpiles as necessary
